This site is intended for Healthcare professionals only.

No clinical benefit of Bath additives in child eczema : BMJ

No clinical benefit of Bath additives in child eczema : BMJ

No evidence of clinical benefit from including emollient bath additives in the standard management of eczema in children finds a recent study.

Childhood eczema (also known as atopic eczema or atopic dermatitis) is a common condition that can have a substantial impact on quality of life for children and their families. Guidelines suggest that complete emollient therapy forms the mainstay of treatment for eczema and should be used regularly with topical corticosteroids or topical calcineurin inhibitors, used in addition to flare-ups.

Miriam Santer at the University of Southampton conducted a study to determine both the clinical and cost effectiveness of including emollient bath additives in the management of eczema in children.

The research design was Pragmatic randomized open-label superiority trial with two parallel groups. The study involved 483 children aged 1 to 11 years, with atopic dermatitis. Children with very mild eczema and children who bathed less than once weekly were excluded.

Participants in the intervention group were prescribed emollient bath additives to be used regularly for 12 months. The control group was asked to use no bath additives for 12 months. Both groups continued with standard eczema management, including leave-on emollients, and caregivers were given standardized advice on how to wash participants.

Eczema control was measured weekly for 16 weeks using the patient-oriented eczema measure (POEM, scores 0-7 mild, 8-16 moderate, 17-28 severe).

The researchers found no statistically significant difference in weekly POEM scores between the two groups over the 16 week period (mean POEM score of 7.5 in the bath additives group and 8.4 in the no bath additives group).

After taking account of eczema severity and other factors that could have affected the results, the POEM score in the no bath additives group was 0.41 points higher than in the bath additives group over 16 weeks, which is substantially lower than the minimal clinically important difference for POEM of 3 points.

Carsten Flohr, Head, Unit for Population-Based Dermatology Research says: “Important remaining evidence gaps are optimal regimen for leave-on treatments, soap substitutes, and frequency of bathing in children with eczema.”

So there is still some room for further work, “but it is heartening to see that an important evidence gap has been closed,” he concludes.

However there was a  possibility of a small benefit among children bathing more than five times a week or among children aged less than 5 years, but according to the researchers, differences are sufficiently small to be clinically useful.

The study concluded that no evidence of clinical benefit from including emollient bath additives in the standard management of eczema in children. Further research is needed into optimal regimens for leave-on emollient and soap substitutes study was published in the journal The BMJ

For more information log on to the journal


The following two tabs change content below.
Vinay Singh

Vinay Singh

Vinay Singh joined Medical Dialogue as Desk Editor in 2018. He covers the medical speciality news in different medical categories including Medical guidelines, updates from Medical Journals and Case Reports. He completed his graduation in Biotechnology from AAIDU and did his MBA from IILM Gurgaon. He can be contacted at . Contact no. 011-43720751
Source: with inputs from the journal BMJ

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted